WHEN THE SMOKE CLEARS

Editor, Dr. Howard Scher—Expert interviews filter through the media flurry that follows major trial results to provide the true clinical implications of large and timely studies.

Page 1 of 2

« start ‹ previous ... 1 2 ... next › end »

Dr. Howard Scher on Circulating Tumor Cells

Howard Scher, MD, 2011 Oct 6

Dr. Howard Scher, MD, is Chief, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center. Prostate cancer is a heterogeneous disease...

An Update on Use of Bone-Directed Therapies in Patients With Cancer: Interview With Dr. Allan Lipton

L Scott Zoeller, 2011 Sept 21, OncologySTAT Editorial Team

OncologySTAT: Where are we right now with bisphosphonates in terms of risk/benefit assessment in patients with cancer? Dr. Lipton: Prior to the approval of pamidronate in the early 1990s, there was no...

Gastroesophageal Junction Adenocarcinoma: Interview With Dr. David Ilson

L Scott Zoeller, 2011 Jul 14, OncologySTAT Editorial Team

David H. Ilson, MD, PhD, is Associate Professor of Medicine, Weill Cornell Medical College, and Associate Attending Physician, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center,...

Pancreatic Cancer—We Have a Lot of Work to Do: Interview With Dr. Jordan Berlin

L Scott Zoeller, 2011 Jul 12, OncologySTAT Editorial Team

Dr. Berlin is Associate Professor of Medicine, Clinical Director, Gastrointestinal Oncology Director, Phase I Program and Medical Director, Clinical Trials Shared Resources at Vanderbilt University School...

Treatment of Myelofibrosis—Where Are We Now? Interview With Dr. Ronald Hoffman

L Scott Zoeller, 2011 Jun 22, OncologySTAT Editorial Team

Ronald Hoffman, MD, is Professor of Medicine, Hematology, and Medical Oncology and Professor of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY. OncologySTAT: Dr. Hoffman, would you...

Chronic Lymphocytic Leukemia—What We've Learned and Where We're Headed: Interview With Dr. Kanti Rai

Interview by Lauren Scott Zoeller, 2011 Apr 21, OncologySTAT Editorial Team

Kanti Rai, MD is Chief, Division of Hematology/Oncology at Long Island Jewish Medical Center in New Hyde Park, New York and Professor of Medicine at Hofstra North Shore-LIJ School of Medicine. OncologySTAT:...

Treatment Approaches for Follicular Lymphoma Continue to Evolve: Interview With Dr. Andre Goy

Interview by L Scott Zoeller, 2011 Jan 11, OncologySTAT Editorial Team

Dr. Andre Goy is Deputy Director and Chief, Lymphoma and Director, Clinical and Translational Cancer Research, at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New...

Is Myeloma Curable? Where Does Auto Transplant Fit in the Wake of Novel Therapies? Interview With Dr. Sundar Jagannath

Interview by L Scott Zoeller, 2010 Dec 2, OncologySTAT Editorial Team

Sundar Jagannath, MD, is Director of Multiple Myeloma Program at Mount Sinai School of Medicine in New York. OncologySTAT: Is multiple myeloma a curable disease?Dr. Jagannath: We are working toward making...

CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley

Interview by L Scott Zoeller, 2010 Nov 23, OncologySTAT Editorial Team

Abstract Dr. Jane Apperley is Professor of Hemato-oncology, Imperial College London. Part I: First-Line TherapyImatinib vs newer agentsOncologySTAT: Dr. Apperley, would you talk about the changing landscape...

CML—What to do About Imatinib Resistance; When to Consider Transplant: Part II: Interview With Dr. Jane Apperley

Interview by L Scott Zoeller, 2010 Nov 23, OncologySTAT Editorial Team

Abstract Dr. Jane Apperley is Professor of Hemato-oncology, Imperial College London. In part I of this interview, Dr. Apperley discusses treatment options for patients with newly diagnosed CML.Part II:...

« start ‹ previous ... 1 2 ... next › end »

Page 1 of 2

Comment Print page RSS feeds

Section Editor

Dr. Howard Scher is Section Editor of When the Smoke Clears.

Read his Letter ›

Meet Our Experts

Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.

View the boards ›